Chemed (CHE) Announces Earnings Results

Chemed (NYSE:CHE) announced its quarterly earnings results on Monday, October 29th. The company reported $3.07 EPS for the quarter, beating the Zacks’ consensus estimate of $2.80 by $0.27, MarketWatch Earnings reports. The business had revenue of $444.15 million during the quarter, compared to analyst estimates of $445.16 million. Chemed had a net margin of 11.73% and a return on equity of 35.13%. Chemed’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.15 EPS. Chemed updated its FY 2018 guidance to $11.80-11.90 EPS and its FY18 guidance to $11.80-11.90 EPS.

Shares of NYSE:CHE traded up $0.14 during midday trading on Thursday, reaching $299.49. The company had a trading volume of 74,826 shares, compared to its average volume of 118,924. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.11 and a current ratio of 1.14. The company has a market capitalization of $4.79 billion, a P/E ratio of 55.88, a price-to-earnings-growth ratio of 2.62 and a beta of 1.23. Chemed has a 52-week low of $234.00 and a 52-week high of $335.99.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Monday, November 12th will be issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend is Thursday, November 8th. Chemed’s dividend payout ratio (DPR) is currently 22.39%.

A number of equities analysts have issued reports on CHE shares. Zacks Investment Research reaffirmed a “buy” rating and set a $342.00 price objective on shares of Chemed in a report on Monday, November 12th. Royal Bank of Canada lifted their price objective on shares of Chemed to $321.00 and gave the stock a “market perform” rating in a report on Monday, July 30th. ValuEngine downgraded shares of Chemed from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 2nd. Finally, Bank of America began coverage on shares of Chemed in a report on Friday, October 12th. They set a “buy” rating and a $390.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $332.00.

In other Chemed news, VP Michael D. Witzeman sold 1,706 shares of the company’s stock in a transaction dated Friday, August 24th. The shares were sold at an average price of $322.00, for a total transaction of $549,332.00. Following the sale, the vice president now directly owns 4,000 shares of the company’s stock, valued at $1,288,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider David Patrick Williams sold 10,000 shares of the company’s stock in a transaction dated Tuesday, November 20th. The shares were sold at an average price of $302.30, for a total value of $3,023,000.00. Following the sale, the insider now owns 24,918 shares in the company, valued at $7,532,711.40. The disclosure for this sale can be found here. Insiders sold a total of 25,990 shares of company stock worth $8,017,220 over the last three months. 4.90% of the stock is owned by insiders.

WARNING: “Chemed (CHE) Announces Earnings Results” was originally published by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://theenterpriseleader.com/2018/11/22/chemed-che-posts-earnings-results-beats-estimates-by-0-27-eps.html.

About Chemed

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Featured Story: What is an Initial Public Offering (IPO)?

Earnings History for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply